Q-omics provides the consensus-scored CTNNA2 profile across patient tissues and cancer cell-line models. CTNNA2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CTNNA2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CTNNA2 RNA expression shows 13,280 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where CTNNA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTNNA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTNNA2 survival associations across molecular data types. CTNNA2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTNNA2 RNA expression–survival associations across cancer types. High CTNNA2 expression shows unfavorable associations in KIRC, KIRP and THCA, but favorable associations in UCEC, OV and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CTNNA2 RNA expression.
This table summarizes CTNNA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CTNNA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTNNA2 shows lower tumor expression in HNSC, COAD, KIRC and BLCA and higher tumor expression in KICH and UCEC. The HNSC box plot shows higher CTNNA2 RNA expression in normal versus tumor tissue (log2 FC = −0.060, t-test p < 0.001).
This table shows molecular features associated with CTNNA2 in patient tissues and cancer cell lines. In patient samples, CTNNA2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CTNNA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and OVARY.
